In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK acquires dermatology company Stiefel for $3.6bn

Executive Summary

About a month after rumors surfaced that it was up for sale, private skin care player Stiefel Laboratories announced it will be acquired by GlaxoSmithKline for $2.9bn cash and the assumption of $400mm in debt. Stiefel shareholders are entitled to $300mm in performance-based earn-outs.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies